Online citations, reference lists, and bibliographies.
← Back to Search

Weight Gain And Hair Loss During Anti-TNF Therapy

Abdo Lutf, M. Hammoudeh
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Objectives. To investigate the incidence of weight gain and hair loss as adverse effects of anti-TNF therapy in rheumatic diseases. Methods. Patients using anti-TNF therapy, who are followed in rheumatology clinic, were interviewed using a questionnaire to investigate the side effects of anti-TNF therapy. Patients who complained of hair loss and weight gain were asked additional questions concerning the relationship of these adverse effects to anti-TNF use, whether therapy was stopped because of these adverse effects and if the adverse effects reversed after stopping therapy. The files were reviewed to follow the weight change before, during, and after discontinuation of anti-TNF. Results. One hundred fifty consecutive patients (82 RA, 34 ankylosing spondylitis, 32 psoriatic arthritis, and 4 for other indications) were interviewed .Weight gain was observed in 20 patients (13.3%) with average gain of 5.5 Kg. Anti-TNF was stopped in five patients because of this adverse effect. Hair loss during anti-TNf therapy was reported in five females (3.3%) and anti-TNF therapy was stopped in all of them. Conclusion. Weight gain and hair loss appear to be associated with anti-TNF therapy and may be one reason for discontinuing the therapy.
This paper references
Adali - mumab , a fully human anti - tumor necrosis factor α monoclonal antibody , for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate : the ARMADA trial
R. W. Martin (2003)
J. M. Bathon (2000)
G. S. Metsios (2007)
Alopecia areata as another immune‐mediated disease developed in patients treated with tumour necrosis factor‐α blocker agents
M. Ferrán (2011)
Impact of anti - tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis
A. Tierney (2010)
Prospective assessment of body weight
K. Briot (2008)
I and J
William M. Marsden (2012)
and R
N. Alcorn (2010)
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
R. Maini (1999)
Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment.
K. Briot (2008)
Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months
Inga-Lill Engvall (2010)
Impact of anti-tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis
N. Alcorn (2010)
[Alopecia areata during anti-TNF alpha therapy: Nine cases].
E. Le Bidre (2011)
Autoimmune diseases induced by TNF-targeted therapies.
M. Ramos-Casals (2008)
Pelade au cours d’un traitement par anti-TNF alpha : neuf cas
E. Bidre (2011)
Benefits and Adverse Effects of Weight Loss: Observations from the Framingham Study
M. Higgins (1993)
? ? ? ? f ? ? ? ? ?
A. ADoefaa (2003)
Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.
G. Metsios (2007)
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
M. Weinblatt (2003)
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.
J. Bathon (2000)
I and i
K. Barraclough (2001)
and M
M. Ramos-Casals (2008)
E. Le Bidre (2011)
M. Higgins (1993)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar